Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 50.81M P/E - EPS this Y -38.10% Ern Qtrly Grth -
Income -15.96M Forward P/E -2.17 EPS next Y 7.40% 50D Avg Chg -9.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -9.00%
Dividend N/A Price/Book 0.97 EPS next 5Y - 52W High Chg -29.00%
Recommedations 2.50 Quick Ratio 15.74 Shares Outstanding 10.74M 52W Low Chg 16.00%
Insider Own 15.06% ROA -21.81% Shares Float 7.86M Beta 1.40
Inst Own 21.94% ROE -32.93% Shares Shorted/Prior 497.30K/144.56K Price 4.68
Gross Margin - Profit Margin - Avg. Volume 43,791 Target Price 18.00
Oper. Margin - Earnings Date May 7 Volume 30,321 Change -4.29%
About Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc.was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma Inc. News
04/24/24 Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
04/22/24 Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
03/19/24 Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript
03/19/24 LTRN: 2023 Results
03/18/24 Lantern Pharma Inc Reports Progress and Financials for FY 2023
03/18/24 Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
03/15/24 Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
03/11/24 Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
03/07/24 11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds
03/05/24 Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
03/04/24 Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
02/20/24 3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom
02/20/24 LTRN: Spotlighting ADCs & Another Orphan
02/15/24 Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
02/05/24 Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
01/17/24 Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
12/13/23 The 3 Most Undervalued AI Penny Stocks to Buy in December
08:00 AM FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
11/10/23 Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript
11/09/23 LTRN: Three Assets in the Clinic in 3Q:23
LTRN Chatroom

User Image Drugtrade Posted - 7 hours ago

$LTRN goes to zero or $100 no in between as always with bio...loaded 1k shares long

User Image MBWallingford Posted - 1 day ago

$LTRN this feels like a con. Slick CEO, Slick story. Don’t buy it. Go ahead post the hate. Just my opinion. Don’t like it just ignore.

User Image intratio Posted - 3 days ago

$LTRN https://www.intratio.com/stock-forecast/LTRN Lantern Pharma Inc. Our predictive algorithm judges this company s value has a poor setup for the immediate future and has no clear long-term directional perspective

User Image crabbypatty31 Posted - 3 days ago

@thompske Of the 3 I sold today $LTRN was the hardest to let go but I just ran out of patience. Hard to keep holding when you are in the red for a long time and buyouts are pretty rare. I've only had that happen once and I've owned alot of biotechs - maybe just the wrong ones;)))

User Image crabbypatty31 Posted - 3 days ago

@thompske A bit afraid to buy in now but will keep it on the watchlist for Monday am. Sold out of 3 biotechs today because they just keep getting shorted into oblivion. It's exhausting. I sold $GERN, $AKBA and $LTRN. Longs suffer and shorts prevail but I don't short stocks.:)) GLTA!

User Image jheerdink Posted - 6 days ago

$LTRN April’s Webinar Wednesday April 24, 2024 – 1:00pm Eastern "LP-300 in Never-Smokers with Non-small Cell Lung Cancer" Register here: https://bit.ly/3vO117s Join Joseph Treat, MD and Reggie Ewesuedo, MD to explore lung cancer in never-smokers, defining its uniqueness, challenges that patients are facing, and the successes and future of the Harmonic™ Phase 2 clinical trial for LP-300 in never-smokers with non-small cell lung cancer. https://finance.yahoo.com/news/lantern-pharma-launches-webinar-wednesdays-120000071.html

User Image Stock_Titan Posted - 6 days ago

$LTRN Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development https://www.stocktitan.net/news/LTRN/lantern-pharma-launches-webinar-wednesdays-featuring-world-class-x1iuovtte8jx.html

User Image jheerdink Posted - 6 days ago

$LTRN https://www.linkedin.com/posts/lanternpharma_nsclc-activity-7184222742039126019-c_od?utm_source=share&utm_medium=member_ios

User Image Bio_Be_Dirty Posted - 6 days ago

$LTRN hmmm

User Image jheerdink Posted - 6 days ago

$LTRN https://www.linkedin.com/pulse/texploration-profiles-lantern-pharma-david-cain-wg2dc?utm_source=share&utm_medium=member_ios&utm_campaign=share_via

User Image tradingtwenty Posted - 6 days ago

Top 5 after-hours stocks that have trended in the past 24 hours: $RXRX 14.03% 🔥 $AEYE 13.87% $TSLA 13.33% $CYN 8.33% $LTRN 8.32% Link: https://tradingtwenty.com/dashboard/trending/past

User Image jheerdink Posted - 6 days ago

$LTRN "Panna Sharma: AI to Transform Cancer Care and Usher in a New Era of Medicine" https://healthandpharma.net/panna-sharma-ai-cancer-care-medicine-artificial-intelligence

User Image jheerdink Posted - 1 week ago

$LTRN https://www.linkedin.com/feed/update/urn:li:activity:7188207939818516481?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7188207939818516481%2C7188366282226814976%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287188366282226814976%2Curn%3Ali%3Aactivity%3A7188207939818516481%29

User Image jheerdink Posted - 1 week ago

$LTRN "Lantern Pharma Inc. (Nasdaq: LTRN) Pharma Inc. is proud to announce the expansion of our Harmonic™ trial into #Japan and #Taiwan, targeting non-small cell lung cancer (NSCLC) in never-smokers. Led by Dr. Yashushi Goto, a leading clinician-scientist from the National Cancer Center of Japan, this Phase 2 clinical study marks a significant step in addressing the needs of an often overlooked patient population in East Asia. With approximately one-third of all lung cancer patients in East Asia being never-smokers, there is a pressing need for tailored treatment options. By evaluating the efficacy of LP-300 in combination with standard chemotherapy, we aim to provide hope and improved outcomes for never smoker patients with #NSCLC in Japan and Taiwan. Check out the full story here https://bit.ly/4b9K46t #ClinicalTrial #CancerResearch #Oncology #DrugDevelopment " https://www.linkedin.com/posts/lanternpharma_japan-taiwan-nsclc-activity-7188207939818516481-lhbA?utm_source=share&utm_medium=member_ios

User Image mankind1 Posted - 1 week ago

$LTRN Time to load up

User Image jheerdink Posted - 1 week ago

$LTRN "Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population." https://finance.yahoo.com/news/lantern-pharma-receives-regulatory-approval-121200177.html

User Image jacckkmm Posted - 1 week ago

$LTRN only 11 million shares outstanding? Oh yeah

User Image DonCorleone77 Posted - 1 week ago

$LTRN Lantern Pharma receives regulatory approval to expand Harmonic trial Lantern Pharma announced that the company has received regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer, or NSCLC, in never-smokers in both Japan and Taiwan. Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers, or LCINS, has been increasing gradually over time, according to a publication in Translational Lung Cancer Research. The approval to proceed with the Phase 2 clinical trials in Japan and Taiwan are expected to accelerate the collection of patient and response data needed for the next-stage of evaluation and development of LP-300, a therapeutic for the treatment of relapsed and inoperable primary adenocarcinoma of the lung given in combination with chemotherapy Additionally, it may also bring a needed therapeutic option for LCINS diagnosed patients in Japan and Taiwan, where one-third of all lung cancer diagnoses are made among those who have never smoked. Finally, Lantern believes that this improves the positioning for drug-candidate LP-300 to develop collaborative and co-development partnerships with global biopharma companies with a primary focus in serving the Asian markets.

User Image jacckkmm Posted - 1 week ago

$LTRN we run today…

User Image Stock_Titan Posted - 1 week ago

$LTRN Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan https://www.stocktitan.net/news/LTRN/lantern-pharma-receives-regulatory-approval-to-expand-harmonic-m942j7fsfb9o.html

User Image jheerdink Posted - 1 week ago

$LTRN "Our leadership in the innovative use of AI and machine learning to transform costs and timelines in the development of precision oncology therapies has guided three drug development programs in active clinical trials. We believe this pace of development with our focused team and resources should yield significant future benefits for investors and patients as our industry matures, adopts and accepts a data and AI-centric approach to drug development." https://finance.yahoo.com/news/lantern-pharma-inc-reports-progress-213202149.html

User Image MBWallingford Posted - 1 week ago

$LTRN weak, weak financial position. No sales for many years. This an idea right now. A crap shoot at best.

User Image jheerdink Posted - 1 week ago

$LTRN Financial Position: Strong cash position with $41.3 million in cash, cash equivalents, and marketable securities as of December 31, 2023. https://finance.yahoo.com/news/lantern-pharma-inc-reports-progress-213202149.html

User Image MBWallingford Posted - 1 week ago

$LTRN this one is floating in hot air. It maybe worth investing in one day, just not today.

User Image jheerdink Posted - 1 week ago

$LTRN Lantern Pharma is harnessing the power of AI and Machine Learning to Fight Cancer Summary This year, the United States expects to tally more than two million new cancer diagnoses— a first-ever prediction— and more than 611,000 cancer-related deaths. While the death rate from cancer is going down, largely due to improvements in early diagnosis and healthy lifestyle changes, the problem is that fewer people aren’t dying of cancer; that’s because the more people who are diagnosed, statistically the more who will die. https://www.pharmiweb.com/article/lantern-pharma-is-harnessing-the-power-of-ai-and-machine-learning-to-fight-cancer

User Image jheerdink Posted - 2 weeks ago

$LTRN

User Image DarthVestor Posted - 2 weeks ago

$LTRN wow glad I waited. Gonna start buying back now.

User Image dmed2021 Posted - 2 weeks ago

Joe Biden has destroyed the Economy 😡 $AMZN $LUNR $SOFI $LTRN $PLTR

User Image jheerdink Posted - 2 weeks ago

$LTRN Have you seen Think Equity's Report issued on Lantern today. It was titled "Lantern Pharma, Inc. (LTRN - $6.39 - BUY) Leverages AI to Disrupt Oncology Drug Development" Analyst Ashok Kumar, PHD, CFA

User Image jheerdink Posted - 2 weeks ago

$LTRN AACR24 Lantern Poster is now up! https://www.linkedin.com/posts/lanternpharma_aacr-2024-poster-is-up-activity-7184600372257157120-vmcE?utm_source=share&utm_medium=member_ios

Analyst Ratings
HC Wainwright & Co. Neutral Apr 25, 24
EF Hutton Buy Aug 10, 23
EF Hutton Buy Jun 26, 23
HC Wainwright & Co. Neutral May 18, 23
EF Hutton Buy Mar 21, 23
EF Hutton Buy Feb 15, 23
EF Hutton Buy Nov 1, 22
HC Wainwright & Co. Buy Mar 11, 22
HC Wainwright & Co. Buy Nov 2, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fletcher Aaron G.L. 10% Owner 10% Owner Nov 29 Sell 3.44 145,348 499,997 371,950 12/01/23
Kreis Leslie W. 10% Owner 10% Owner Nov 29 Sell 3.44 145,348 499,997 371,950 12/01/23
Kreis Leslie W. 10% Owner 10% Owner Nov 08 Sell 4.4 350,000 1,540,000 164,137 11/09/22
Fletcher Aaron G.L. 10% Owner 10% Owner Nov 08 Sell 4.4 350,000 1,540,000 164,137 11/09/22
Fletcher Aaron G.L. 10% Owner 10% Owner Sep 02 Sell 5.2 6,445 33,514 26,093 09/07/22
Kreis Leslie W. 10% Owner 10% Owner Sep 02 Sell 5.2 6,445 33,514 26,093 09/07/22